Compare · BSX vs HAE
BSX vs HAE
Side-by-side comparison of Boston Scientific Corporation (BSX) and Haemonetics Corporation (HAE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and HAE operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $71.32B, about 23.3x HAE ($3.05B).
- Over the past year, BSX is down 54.0% and HAE is down 2.2% - HAE leads by 51.7 points.
- BSX has been more active in the news (21 items in the past 4 weeks vs 11 for HAE).
- Both have 25 recent analyst ratings on file.
- Company
- Boston Scientific Corporation
- Haemonetics Corporation
- Price
- $47.98-0.74%
- $67.27-0.99%
- Market cap
- $71.32B
- $3.05B
- 1M return
- -16.72%
- +12.04%
- 1Y return
- -53.95%
- -2.22%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 1991
- News (4w)
- 21
- 11
- Recent ratings
- 25
- 25
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Haemonetics Corporation
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, the company offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Latest BSX
- Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest HAE
- SEC Form SD filed by Haemonetics Corporation
- Haemonetics upgraded by BofA Securities with a new price target
- SEC Form 10-K filed by Haemonetics Corporation
- EVP and General Counsel Basil Michelle L covered exercise/tax liability with 2,913 shares and was granted 28,424 shares, increasing direct ownership by 59% to 68,829 units (SEC Form 4) (tax withholding)
- EVP, Chief Operating Officer Chan Frank was granted 27,535 shares and covered exercise/tax liability with 546 shares, increasing direct ownership by 454% to 32,936 units (SEC Form 4) (tax withholding)
- EVP, Chief Financial Officer Darecca James covered exercise/tax liability with 2,505 shares and was granted 29,312 shares, increasing direct ownership by 97% to 54,444 units (SEC Form 4) (for withholding tax)
- VP, Chief Accounting Officer Maunsell Farris Maryanne covered exercise/tax liability with 197 shares and was granted 2,220 shares, increasing direct ownership by 45% to 6,501 units (SEC Form 4) to cover taxes
- EVP, Chief Commercial Officer Galvin Roy covered exercise/tax liability with 879 shares and was granted 27,535 shares, increasing direct ownership by 202% to 39,882 units (SEC Form 4) to satisfy withholding tax
- SVP, Human Resources Miller Laurie A. covered exercise/tax liability with 948 shares and was granted 13,323 shares, increasing direct ownership by 43% to 41,300 units (SEC Form 4) to cover withholding tax
- President & CEO Simon, Christopher covered exercise/tax liability with 9,681 shares and was granted 78,344 shares, increasing direct ownership by 18% to 444,704 units (SEC Form 4) (withholding obligation)